Development of an LC-MS/MS method for aromatase inhibitor screening
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Myeong Hyeon | - |
dc.contributor.author | Kim, In Sook | - |
dc.contributor.author | Dong, Mi-Sook | - |
dc.contributor.author | Yoo, Hye Hyun | - |
dc.date.accessioned | 2021-09-05T09:19:39Z | - |
dc.date.available | 2021-09-05T09:19:39Z | - |
dc.date.created | 2021-06-15 | - |
dc.date.issued | 2014-05 | - |
dc.identifier.issn | 1618-2642 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/98697 | - |
dc.description.abstract | Aromatase (CYP 19A1) is a key steroidogenic enzyme that catalyzes the conversion of androgen to estrogen. In this study, a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for aromatase inhibitor screening was developed and validated. The substrate androstenedione was incubated with human CYP 19A1 supersomes in the presence of NADPH for 30 min, and estrone formation was determined by LC-MS/MS analysis. Cortisone was used as internal standard. The incubation mixture was extracted using a liquid-liquid extraction method with ethyl acetate. Chromatographic separation was achieved using a C-18 column (3.0 x 50 mm, 2.7 mu m) with a mobile phase consisting of 0.1 % formic acid/acetonitrile adopting gradient elution at a flow rate of 0.4 mL/min. The mass spectrometer was operated in positive electrospray ionization mode. The precursor-product ion pairs used for multiple reaction monitoring were m/z 287 -> 97 (androstenedione), m/z 271 -> aEuro parts per thousand 159 (estrone), and m/z 361 -> aEuro parts per thousand 163 (IS, cortisone). The developed method met the required criteria for the validation of bioanalytical methods. The validated method was successfully applied to evaluate aromatase inhibitory activity of plants extracts of Simaroubaceae. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | SPRINGER HEIDELBERG | - |
dc.subject | CYTOCHROME-P450 ENZYMES | - |
dc.subject | BREAST-CANCER | - |
dc.subject | PROFILES | - |
dc.subject | RECEPTOR | - |
dc.subject | CYP19 | - |
dc.subject | ASSAY | - |
dc.title | Development of an LC-MS/MS method for aromatase inhibitor screening | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Dong, Mi-Sook | - |
dc.identifier.doi | 10.1007/s00216-014-7764-1 | - |
dc.identifier.scopusid | 2-s2.0-84901619891 | - |
dc.identifier.wosid | 000336261800022 | - |
dc.identifier.bibliographicCitation | ANALYTICAL AND BIOANALYTICAL CHEMISTRY, v.406, no.14, pp.3443 - 3449 | - |
dc.relation.isPartOf | ANALYTICAL AND BIOANALYTICAL CHEMISTRY | - |
dc.citation.title | ANALYTICAL AND BIOANALYTICAL CHEMISTRY | - |
dc.citation.volume | 406 | - |
dc.citation.number | 14 | - |
dc.citation.startPage | 3443 | - |
dc.citation.endPage | 3449 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Biochemistry & Molecular Biology | - |
dc.relation.journalResearchArea | Chemistry | - |
dc.relation.journalWebOfScienceCategory | Biochemical Research Methods | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Analytical | - |
dc.subject.keywordPlus | CYTOCHROME-P450 ENZYMES | - |
dc.subject.keywordPlus | BREAST-CANCER | - |
dc.subject.keywordPlus | PROFILES | - |
dc.subject.keywordPlus | RECEPTOR | - |
dc.subject.keywordPlus | CYP19 | - |
dc.subject.keywordPlus | ASSAY | - |
dc.subject.keywordAuthor | Aromatase | - |
dc.subject.keywordAuthor | CYP 19A1 | - |
dc.subject.keywordAuthor | Inhibition | - |
dc.subject.keywordAuthor | LC-MS/MS | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.